Benefit of intensified consolidation therapy with and without allogeneic BMT for subsets of high-risk ALL in trial ALL-BFM 90.

被引：0

作者：

Reiter, A

Ebell, W

Schrappe, M

Harbott, J

Ludwig, WD

Klingebiel, T

Zintl, F

Henze, G

Gadner, H

Welte, K

Riehm, H

机构：

[1] HANNOVER MED SCH,D-3000 HANNOVER,GERMANY

[2] BERLIN UKRV,BERLIN,GERMANY

[3] UNIV GIESSEN,GIESSEN,GERMANY

[4] HUMBOLDT UNIV BERLIN,BERLIN,GERMANY

[5] UNIV TUBINGEN,D-72074 TUBINGEN,GERMANY

[6] UNIV JENA,D-6900 JENA,GERMANY

[7] ST ANNA CHILDRENS HOSP,A-1090 VIENNA,AUSTRIA

来源：

BLOOD | 1997年 / 90卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

下载

页码：997 / 997

页数：1

共 50 条

[31] Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial
Attarbaschi, Andishe
Mann, Georg
Zimmermann, Martin
Bader, Peter
Barisone, Elena
Basso, Giuseppe
Biondi, Andrea
Cario, Gunnar
Cazzaniga, Gianni
Colombini, Antonella
Flotho, Christian
Kuhlen, Michaela
Lang, Peter
Lauten, Melchior
Linderkamp, Christin
Locatelli, Franco
Lo Nigro, Luca
Moericke, Anja
Niggli, Felix
Panzer-Gruemayer, Renate
Parasole, Rosanna
Peters, Christina
Putti, Maria Caterina
Rizzari, Carmelo
Suttorp, Meinolf
Valsecchi, Maria Grazia
Conter, Valentino
Schrappe, Martin
LEUKEMIA, 2020, 34 (06) : 1694 - 1700
[32] Comparison of intensive chemotherapy (CHT), allogeneic (ALLO) or autologous (AUTO) stem cell transplantation (SCT) as post-remission therapy in adults with high-risk ALL (HR-ALL). Results of randomized study PETHEMA ALL93
Ribera, JM
Ortega, JJ
Oriol, A
Fontanilias, M
Parody, R
Hernandez-Rivas, JM
Rivas, C
Del Potro, E
Moreno, MJ
Besalduch, J
Fernandez-Calvo, J
Bethencourt, C
Tormo, M
Arias, J
Bueno, J
Ortega, F
Deben, G
Moraleda, JM
Vivancos, P
Guinea, J
Bello, JL
Queizan, JA
Feliu, E
San Miguel, JF
Sanz, MA
BONE MARROW TRANSPLANTATION, 2002, 29 : S5 - S5
[33] Evidence for Heterogeneous Genetic Associations with Acute Lymphoblastic Leukemia (ALL) By Cytogenetics and Sex in High-Risk Patients Treated with Matched Unrelated Donor Allogeneic Blood or Marrow Transplant (URD-BMT)
Clay, Alyssa I.
Hahn, Theresa
Preus, Leah
Onel, Kenan
Zhu, Qianqian
Haiman, Christopher
Stram, Daniel O.
Pooler, Loreall C.
Sheng, Xin
Weisdorf, Daniel
Yan, Li
Liu, Qian
Hu, Qiang
Liu, Song
Battaglia, Sebastiano
Zhu, Xiaochun
Block, AnneMarie W.
Salt, Sheila
Ambrosone, Christine B.
Tritchler, David
Spellman, Stephen R.
Pasquini, Marcelo C.
McCarthy, Philip L.
Sucheston-Campbell, Lara E.
BLOOD, 2015, 126 (23)
[34] Genome-Wide Association Study (GWAS) of High-Risk Minimal Residual Disease and Relapse in B-Cell Acute Lymphoblastic Leukemia on Trial AIEOP-BFM ALL 2000
Hinze, Laura
Junk, Stefanie V.
Klein, Norman
Moricke, Anja
Cario, Gunnar
Kratz, Christian P.
Houlston, Richard S.
Bartam, Claus R.
Koehler, Rolf
Zimmermann, Martin
Schrappe, Martin
Stanulla, Martin
BLOOD, 2017, 130
[35] Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 (vol 111, pg 4477, 2008)
Moricke, A.
Reiter, A.
Zimmermann, M.
Gadner, H.
Stanulla, M.
Dordelmann, M.
Loning, L.
Beier, R.
Ludwig, W. D.
Ratei, R.
Harbott, J.
Boos, J.
Mann, G.
Niggli, F.
Feldges, A.
Henze, G.
Welte, K.
Beck, J. D.
Klingebiel, T.
Niemeyer, C.
Zintl, F.
Bode, U.
Urban, C.
Wehinger, H.
Niethammer, D.
Riehm, H.
Schrappe, M.
BLOOD, 2009, 113 (18) : 4478 - 4478
[36] Comparison of intensive chemotherapy (CHT), allogeneic (ALLO) or autologous (AUTO) stem cell transplantation (SCT) In children with very high-risk acute lymphoblastic leukemia (ALL).: Results of prospective randomized PETHEMA-ALL93 trial
Ribera, JM
Ortega, JJ
Oriol, A
Fontanillas, M
Bastida, P
Calvo, C
Carboné, A
González-Valentin, ME
Martín-Reina, V
Molinés, A
Egurbide, I
Moreno, MJ
Fernández-Calvo, J
BONE MARROW TRANSPLANTATION, 2002, 29 : S74 - S74
[37] Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome
Sanz, Miguel A.
Montesinos, Pau
Rayon, Chelo
Holowiecka, Alexandra
de la Serna, Javier
Milone, Gustavo
de Lisa, Elena
Brunet, Salut
Rubio, Vicente
Ribera, Jose M.
Rivas, Concha
Krsnik, Isabel
Bergua, Juan
Gonzalez, Jose
Diaz-Mediavilla, Joaquin
Rojas, Rafael
Manso, Felix
Ossenkoppele, Gert
Gonzalez, Jose D.
Lowenberg, Bob
BLOOD, 2010, 115 (25) : 5137 - 5146
[38] Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with Non-B-Cell acute lymphoblastic leukemia - The Israel National Study Report
Stark, B
Sharon, R
Rechavi, G
Attias, D
Ballin, A
Cividalli, G
Burstein, Y
Sthoeger, D
Abramov, A
Zaizov, R
CANCER, 2000, 88 (01) : 205 - 216
[39] Value of high-dose ara-C during the interval-therapy of a BFM-like protocol in children with increased risk all and NHL: Results of the EORTC 58881 trial.
Millot, F
Suciu, S
Philippe, N
Benoit, Y
Nelken, B
Uyttebroeck, A
Mechinaud, F
Vilmer, E
Robert, A
Boutard, P
Margueritte, G
Ferster, A
Plouvier, E
Rialland, X
Behar, C
Plantaz, D
Dresse, MF
Philippet, P
Waterkeyn, C
Otten, J
Guilhot, F
BLOOD, 1999, 94 (10) : 382A - 382A
[40] Clinical Outcomes of Patients With High-Risk Acute Promyelocytic Leukemia (APL) Treated With All-Trans Retinoic Acid (ATRA)/Arsenic Trioxide (ATO)-Based Induction and Consolidation Without Maintenance Therapy: A Single-Institution Study
Yohannan, Binoy
Sharma, Akanksha
Sridhar, Arthi
Cervoni-Curet, Frances
Rios, Adan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S269 - S269

← 1 2 3 4 5 →